MC

459.25

-1.36%↓

SANES

9.484

-1.2%↓

SAF

283.6

-1.46%↓

BBVA

18.26

-0.79%↓

BNP

83.02

-0.41%↓

MC

459.25

-1.36%↓

SANES

9.484

-1.2%↓

SAF

283.6

-1.46%↓

BBVA

18.26

-0.79%↓

BNP

83.02

-0.41%↓

MC

459.25

-1.36%↓

SANES

9.484

-1.2%↓

SAF

283.6

-1.46%↓

BBVA

18.26

-0.79%↓

BNP

83.02

-0.41%↓

MC

459.25

-1.36%↓

SANES

9.484

-1.2%↓

SAF

283.6

-1.46%↓

BBVA

18.26

-0.79%↓

BNP

83.02

-0.41%↓

MC

459.25

-1.36%↓

SANES

9.484

-1.2%↓

SAF

283.6

-1.46%↓

BBVA

18.26

-0.79%↓

BNP

83.02

-0.41%↓

Search

Equasens

Fermé

33.95 -2.86

Résumé

Variation du prix de l'action

24h

Actuel

Min

33.45

Max

34.6

Chiffres clés

By Trading Economics

Revenu

17M

Ventes

116M

P/E

Moyenne du Secteur

14.895

Rendement du dividende

3.54

Marge bénéficiaire

14.879

Employés

1,400

EBITDA

116M

Dividendes

By Dow Jones

Rendement du dividende

Moyenne du Secteur

3.54%

Prochains Résultats

30 mars 2026

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

535M

Ouverture précédente

36.81

Clôture précédente

33.95

Equasens Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

23 mars 2026, 23:47 UTC

Acquisitions, Fusions, Rachats

Gilead Sciences to Buy Ouro Medicines, Collaborate With Galapagos on Purchased Assets -- Update

23 mars 2026, 22:55 UTC

Acquisitions, Fusions, Rachats

Gilead Sciences to Buy Ouro Medicines for Up to $2.18 Billion

23 mars 2026, 21:51 UTC

Acquisitions, Fusions, Rachats

Italy's Postal Service Makes $12.50 Billion Bid for Telecom Italia -- 3rd Update

23 mars 2026, 23:59 UTC

Market Talk

Global Equities Roundup: Market Talk

23 mars 2026, 23:59 UTC

Market Talk

Woodside, Santos Earnings Power Up on Surging LNG Prices -- Market Talk

23 mars 2026, 23:50 UTC

Market Talk

Nikkei May Rise on Hopes for U.S. Talks With Iran -- Market Talk

23 mars 2026, 23:37 UTC

Market Talk

Gold Rises, Boosted by Fall in Dollar, U.S. Treasury Yields -- Market Talk

23 mars 2026, 22:42 UTC

Market Talk
Principaux Événements d'Actualité

Global Equities Roundup: Market Talk

23 mars 2026, 22:42 UTC

Market Talk
Principaux Événements d'Actualité

Bell Potter Names Miners Less Exposed to Fuel Price, Supply Risks -- Market Talk

23 mars 2026, 22:40 UTC

Acquisitions, Fusions, Rachats

Gilead Sciences to Buy Ouro Medicines for Up to $2.18B

23 mars 2026, 22:23 UTC

Market Talk

Apollo Debt Solutions Shrugs Off Private-Credit Fears -- Market Talk

23 mars 2026, 22:22 UTC

Acquisitions, Fusions, Rachats

Gilead Sciences: OM336 Is for Treatment of Autoantibodies Driven Immune-Mediated Disease

23 mars 2026, 22:21 UTC

Acquisitions, Fusions, Rachats

Gilead Sciences: Company Would Pay Galapagos Royalties of 20%-23% of Net OM336 Sales

23 mars 2026, 22:21 UTC

Acquisitions, Fusions, Rachats

Gilead Sciences: Company Would Retain Sole Worldwide Commercialization Rights of OM336 Outside of Greater China

23 mars 2026, 22:20 UTC

Acquisitions, Fusions, Rachats

Gilead Sciences: Company, Galapagos Would Collaborate on Development of OM336 >GILD

23 mars 2026, 22:20 UTC

Acquisitions, Fusions, Rachats

Gilead Sciences: Galapagos Would Absorb Substantially All of Ouro's Operating Assets, Retain Its Employees >GILD

23 mars 2026, 22:19 UTC

Acquisitions, Fusions, Rachats

Gilead Sciences: Galapagos Would Pay 50% of Upfront Consideration and 50% of Any Contingent Milestone Payments Payable to Ouro Shareholders

23 mars 2026, 22:19 UTC

Acquisitions, Fusions, Rachats

Gilead Sciences: Currently in Advanced Discussions With Galapagos With Respect to Potential Research-and-Development Collaboration on Acquired Ouro Assets

23 mars 2026, 22:18 UTC

Acquisitions, Fusions, Rachats

Gilead Sciences to Buy Ouro Medicines for About $1.68B Upfront, Up to $500M in Contingent Milestone Payments >GILD

23 mars 2026, 22:15 UTC

Acquisitions, Fusions, Rachats

Gilead Sciences To Acquire Ouro Medicines To Advance First In Class T Cell Engager Program For Autoimmune Diseases >GILD

23 mars 2026, 22:08 UTC

Market Talk

Ebos Needs to Reset Its Gearing Targets -- Market Talk

23 mars 2026, 21:42 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

23 mars 2026, 21:42 UTC

Market Talk

RBNZ's Breman Strikes Reassuring Tone On Rates -- Market Talk

23 mars 2026, 21:32 UTC

Résultats

WuXi XDC Cayman: Results Aided by Strong Growth in Contract Research, Development and Manufacturing Organisation Business>2268.HK

23 mars 2026, 21:32 UTC

Résultats

WuXi XDC Cayman 2025 Net CNY1.56B Vs. Net CNY917.16M >2268.HK

23 mars 2026, 21:32 UTC

Résultats

WuXi XDC Cayman 2025 Rev CNY5.94B Vs. CNY4.05B >2268.HK

23 mars 2026, 21:10 UTC

Principaux Événements d'Actualité

Oil Is Back Under $100. Trump Says Iran Has Agreed to No Nuclear Weapons. -- Barrons.com

23 mars 2026, 20:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

23 mars 2026, 20:50 UTC

Market Talk

Health Care Roundup: Market Talk

23 mars 2026, 20:50 UTC

Market Talk
Résultats
Principaux Événements d'Actualité

Basic Materials Roundup: Market Talk

Comparaison

Variation de prix

Equasens prévision

Note du Consensus

By TipRanks

0 ratings

0

Achat

0

Maintien

0

Vente

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Equasens

Equasens Société anonyme provides healthcare IT solutions in Europe. The company develops electronic equipment, digital and robotic health, and equipment lease financing solutions. It also offers id., a pharmacy management software suite; id. PATIENT for the exchange of healthcare data; id. VENTE, which facilitates and secures prescription sales; id. COMMANDE, which manages orders and inventory; dispensing robots; Ségur id. services; FARMACLICK, a communication protocol; DIFARM, a modular solution for wholesalers-distributors; and PHARE, a retail management tool. In addition, the company offers patient medication adherence, patient loyalty, point-of-sale commercial performance, piloting pharmacy operations, pharmacy team training, securing pharmacy operations and health data, and digital communication solutions; and in-home nursing services and hospital-at-home, hospitals, and telemedicine solutions. Further, it provides id. DESK, an informative and interactive dashboard; id. UP!, a smartphone app; id. EASYQ, a queuing management solution; Miaterapia, a patient app; and MediStory for tracking patient records; ExpressVitale module; and MEDILINK, a health data hosting provider. Additionally, the company offers KAP&LINK2, a terminal with smart card and NFC reader; eS-KAP-Ad, a mobile device with a pre-loaded software; KAP-INSIDE, a mobile terminal; TI-KAP, which allows access to contact and contactless cards; AUTHENTIFICATEUR, a patented patient authentication system; KAP'TEUR by KAPELSE, a patented universal sensor; and NOVIAcare, which analyzes the behavior and activity of the elderly. It serves nursing homes, hospitals, in-house nursing care and hospital-at-home programs, regional health professional communities, multidisciplinary group practices, and individual healthcare professionals. The company was incorporated in 1996 and is headquartered in Villers-les-Nancy, France. Equasens Société anonyme is a subsidiary of Marque Verte Sante.
help-icon Live chat